BioLife Solutions, Inc. Message Board

The article is correct but I bet that as soon as the stock hits new highs they'll start putting negative reports out there. They did it with one of my other positions. SA will argue that different columnists write thier opinion. Well, sure, but the timing of the release of different reports matches perfectly the ups and downs.Also, why do they let different columnists write about the same stock? For the experienced investors sometimes their arguments look very superficial and manipulative. For instance, a columnist wrote that a stock was a scam because it went public through a reverse merger and not IPO - very shallow argument, so did US Airways, Clearwire, NYSE and others. For a independent opinion try some research firm.

Sentiment: Strong Buy

wow up 34% today!

"An increase in comp valuations over the last several weeks has had the effect of moving our price target from $0.70/share to $0.90/share."

Sentiment: Strong Buy

Just like days of old.

To move this stock? Great news all around, especially the most recent Seeking Alpha article! No one is willing to sell at these levels. Is there just not enough buying interest yet? Curious what others think...

Sentiment: Strong Buy

Hi Guys ..

Intelgenx launched their first drug Forfivo in October this will drive Intelgenx into Profitability this Year because of its very low burn-rate of around $1.2 Mil a year !

IGXT Submits NDA for Anti-Migraine Versafilm to FDA in March another 1x NDA filing for Erectile Dysfunction Versafilm and 2x ANDA filings expected in 1H 2013. Two Partnerships for Anti-Migraine and Erectile Dysfunction products is expected in 1H 2013 too which means more Cash for Intelgenx .Intelgenx has 9x Drugs in late stage which will be all on the Market within next 2-3 years .

IGXT has NO DEBT and Cash untill 2016 means enough to drive this Company into Profitability which is expected for this Year . Current Market Cap of just $33 M is really Brutally Underpriced .

IGXT has the Potential to hit $10++ within 2 Year ! GLTA

Intelgenx (IGXT)

Market Cap : $33.7 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year

Price : $0.67

Shares Out : 50 M ( 20 M shares are held by Insiders & Institutions)

March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.

"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.

-----------------

Positive cashflow, revenue expectations for 2013 set higher than 2012 by the company
It'll be around or above $1/share by the end of the year

Sentiment: Strong Buy

and evidently everyone else is also.

BLFS is growing its business while keeping high growth as the regenerative medicine market opportunity develops.” BLFS hold the leading supplier position for pre-formulated, clinical grade bio-preservation media products. We estimate that our HypoThermosol^® cell/tissue storage medium and CryoStor^® cryopreservation freeze media products are used in more than 50 clinical trial-stage cell and tissue based therapies in the regenerative medicine field; any 1 of which could generate $1 M per year in revenue, if regulatory and marketing approvals are obtained by our customers. BLFS closed at $0.29 on no volume on Thursday, 3/29/13. As traders stayed silent post seeking profit and always seems to pop back. I am still … optimistic about BLFS, now that Q4 and FY12 results are out – my expectations are on target – yet again as BLFS focuses another “rebound” play! The 50 day moving average is up to $0.30 and the 200 day average is up $0.28. The float is only 19.02 M as compared to outstanding shares of 69.67 M. I continue to reiterate this as a “STRONG BUY”

Sentiment: Strong Buy

comments welcome